First Vet RCT Reinforces Diagnostic Power of ODM

A newly-published study proves once again how oesophageal Doppler monitoring (ODM) can provide a uniquely accurate, real-time haemodynamic picture. The randomised, triple blinded, placebo-controlled study from Sández et al investigated the effect of a drug which improves cardiac output and contractility, in dogs with mitral valve disease and dilated cardiomyopathy. 

Published here, investigators used ODM to assess inotropic and vasodilator drug Pimobendan. They conclude that it increases systolic flow and contractility parameters from the first minute after administration. Based on the results, they assert that Pimobendan could be used to improve haemodynamic status during general anaesthesia in senior dogs without cardiac pathology. 

Only ODM is able to monitor the parameters required to support this conclusion in real time. Indeed, for Deltex, CEO Andy Mears says; “The take-home message for me is that our technology has provided precisely the information required to assess the impact of this drug. The right information at the right time is really all that matters when isolating the impact of a drug intervention. As with our unparalleled bank of human clinical data, yet again we can show how ODM provides continuous, accurate data in real time. It’s a fantastic study and I’m delighted to see a first RCT for ODM in dogs.”

Terminus Road | Chichester | PO19 8TX | United Kingdom

  • Enquiries: +44 1243 774837
  • Email:
  • Deltex App:


Registered in England & Wales Company No: 1691369